Cell line · CVCL_3881
Papers46
1 to 20 of 46
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combined action of suicide gene exosomes from pancreatic cancer-associated fibroblasts and from mesenchymal stem cells as a pancreatic ductal adenocarcinoma treatment approach. | Cancer Cell Int | 2025 | Its Methods give the RRID and name the line | PubMed | |
| IFN-γ-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. | J Exp Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Placental co-transcriptional activator Vestigial-like 1 (VGLL1) drives tumorigenesis via increasing transcription of proliferation and invasion genes. | Front Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. | bioRxiv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Evaluations of an Early Change in Tumor Pathophysiology in Response to Radiotherapy with Oxygen Enhanced Electron Paramagnetic Resonance Imaging (OE EPRI). | Mol Imaging Biol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. | Cell Death Discov | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Non-canonical functions of SNAIL drive context-specific cancer progression. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition. | Clin Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_3881/papers